Classifications: blood former; hematopoietic growth factor; Therapeutic: hematopoietic growth factor
Prototype: Epoetin alfa
Pregnancy Category: C
5 mg injection
Hematopoietic growth factor (interleukin-11) that is produced by recombinant DNA.
Indicated by return of postnadir platelet count toward normal (≥50,000).
Increases platelet count in a dose-dependent manner.
Prevention of severe thrombocytopenia following myelosuppressive chemotherapy (not effective after myeloablative chemotherapy).
Hypersensitivity to oprelvekin; myeloablative chemotherapy; myeloid malignancies; pregnancy (category C).
Patients with left ventricular dysfunction, cardiac disease, CHF, history of atrial arrhythmias, or other arrhythmias; electrolyte
imbalance, hypokalemia; respiratory disease; papilledema; thromboembolic disorders; older adults; cerebrovascular disease,
stroke, TIAs; pleural effusion, pericardial effusion, ascites; increased intracranial pressure, brain tumor, visual disturbances;
hepatic or renal dysfunction; lactation.
Route & Dosage
Adult: SC 50 mcg/kg once daily starting 624 h after completing chemotherapy and continuing until platelet count is ≥50,000
cells/mcL or up to 21 d
Child (8 mo17 y): SC 75100 mcg/kg once daily starting 624 h after completing chemotherapy and continuing until platelet count is
≥50,000 cells/mcL or up to 21 d
- Note: Do not use if solution is discolored or if it contains particulate matter.
- Reconstitute solution by gently injecting 1 mL of sterile water for injection (without preservative) toward the sides of
the vial. Keep needle in vial and gently swirl to dissolve but do not shake solution. Without removing needle, withdraw specified
amount of oprelvekin for injection.
- Give as single dose into the abdomen, thigh, hip, or upper arm.
- Discard any unused portion of the vial. It contains no preservatives.
- Use reconstituted solution within 3 h; store at 2°8° C (36°46° F) until used.
- Store unopened vials at 2°8° C (36°46° F). Do not freeze.
Adverse Effects (≥1%)Body as a Whole: Edema, neutropenic fever, fever,
asthenia, pain, chills, myalgia, bone pain, dehydration. CNS: Headache, dizziness, insomnia,
nervousness. CV: Tachycardia,
vasodilation, palpitations, syncope, atrial fibrillation/flutter, peripheral edema, capillary leak syndrome
. GI: Nausea, vomiting, mucositis, diarrhea,
oral moniliasis, anorexia, constipation
, dyspepsia. Hematologic:
Ecchymosis. Respiratory: Dyspnea, rhinitis, cough, pharyngitis,
pleural effusion, pulmonary
edema, exacerbation of preexisting pleural effusion. Skin: Alopecia
skin discoloration, exfoliative dermatitis. Special Senses:
Conjunctival injection, amblyopia.
No clinically significant interactions established.
80% from SC injection site. Onset:
Days 59. Duration:
7 d after last dose. Distribution:
Distributes to highly perfused organs. Elimination:
In urine. Half-Life:
Assessment & Drug Effects
- Lab tests: Monitor platelet counts until adequate recovery; periodically monitor CBC with differential and serum electrolytes.
- Monitor carefully for and immediately report S&S of fluid overload, hypokalemia, and cardiac arrhythmias.
- Monitor persons with preexisting fluid retention carefully (e.g., CHF, pleural effusion, ascites) for worsening of symptoms.
Patient & Family Education
- Review patient information leaflet with special attention to administration directions.
- Report any of the following to the physician: Shortness of breath, edema of arms and/or legs, chest pain, unusual fatigue
or weakness, irregular heartbeat, blurred vision.